natgillin/translations-raw huggingface dataset:
an oxygen monitor to monitor the oxygen content of the exhaust gas from the oxidation catalyst; 
- < monitor kisika za praćenje sadržaja kisika u ispušnom plinu iz oksidacijskog katalizatora;
and/or in the preparation of compound 5, the mole ratio of compound 6 to compound 7 is in the range of 1.0-4.0; 
i / ili u pripremi spoja 5, molni odnos spoja 6 prema spoju 7 je u rasponu 1,0-4,0;
Specifically, the compound is coupled to a ligand or carrier moiety. Specific embodiments refer to the treatment wherein the compound is administered in a pharmaceutical preparation for oral, parenteral, systemic, mucosal, topic, rectal, sublingual, buccal or implant use which preparation comprises a pharmaceutically acceptable carrier, preferably wherein the pharmaceutical preparation is a tablet, dermal or transdermal formulation, ointment, gel, cream, lotion, patch, solution, injectable, ophtalmic solution, disperse system, emulsion, microencapsulated drug system, osmotic pump, subdermal implant, granule, microsphere, modified-release system, targeted release system, granules, or pill. 
Spoj artemizinina namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što se spoj primijenjuje u farmaceutskom pripravku namijenjenom oralnoj, parenteralnoj, sistemnoj, mukozalnoj, topikalnoj, rektalnoj, sublingvalnoj, bukalnoj ili implantatnoj upotrebi, gdje navedeni pripravak sadrži farmaceutski prihvatljivi nosač, po mogućnosti gdje je farmaceutski pripravak tableta, dermalna ili transdermalna formulacija, mast, gel, krema, losion, flaster, otopina, injekcijska otopina, otopina za oči, disperzni sustav, emulzija, sustav s mikroenkapsuliranim lijekom, osmotska crpka, subdermalni usadak, granula, mikrosfera, sustav za modificirano otpuštanje, sustav s ciljanim otpuštanjem, granule ili pilula.
A process for the production of furan derivatives from D-glucose, wherein D-glucose is converted into D-fructose in an enzymatic process, wherein redox cofactors are used and regenerated, whereby, as a result of at least two further enzymatically catalyzed redox reactions proceeding in the same reaction batch, one of the two redox cofactors accumulates in its reduced form and, respectively, the other one in its oxidized form, whereby D-glucose is converted into D-fructose, involving two or more oxidoreductases, and 
Postupak za proizvodnju derivata furana iz D-glukoze, naznačen time, da A) D-glukoza se pretvara u D-fruktozu u enzimskom postupku, korištenjem i obnavljanjem redoks kofaktora, pri čemu se D-glukoza pretvara u D -fruktozu, koja uključuje dvije ili više oksidoreduktaze u reakcijama dobivanja proizvoda, te, tijekom pretvorbe D- glukoze u D-fruktozu, isprva enzimska katalizirana redukcija u D-sorbitol, te, potom, enzimska katalizirana oksidacija D-sorbitola do D-fruktoze, pri čemu se NAD +/ NADH i NADP + / NADPH koriste kao redoks kofaktori i, kao rezultat barem dvije daljnje enzimski katalizirane redoks reakcije koje se odvijaju u istoj reakcijskoj šarži, jedan od dva redoks kofaktora akumulira se u svojem reduciranom obliku, odnosno drugi u oksidiranom obliku, i B) D-fruktoza se pretvara u derivate furana i u koraku A)
In a fourth class of this embodiment, the active pharmaceutical ingredient in such compositions comprises about 75% to about 100% by weight of the crystalline monohydrate. 
U četvrtoj klasi ove implementacije, aktivan farmaceutski sastojak u takvim pripravcima sadržava oko 50% do oko 100% težinski kristalnog monohidrata.
The compound of aspect 1 or 2, wherein the R3 group is selected from the group consisting of H, methyl, and trifluoromethyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se skupinu R; bira iz skupine koju čine H, metil, te trifluormetil.
An appliance according to claims 2, wherein said ventilation opening is disposed at a lower portion of the casing (11). 
Uređaj u skladu s patentnim zahtjevima 2, naznačen time što je navedeni ventilacijski otvor smješten na donjem dijelu kućišta (11).
reacting the compound of the Formula VII with a suitable chlorinating agent in the presence of a suitable base and a suitable solvent, wherein the reaction is carried out by: 
reakciju spoja formule VII sa prikladnim agensom za kloriranje u prisutnosti prikladne baze i prikladnog otapala, gdje se reakcija provodi uz:
The apparatus of claim 1, wherein the L1 signaling information includes FEC type information of the PLP data. 
Uređaj prema zahtjevu 1, gdje LI signalne informacije obuhvaćaju FEC tip informacija PLP podataka.
A blast-resistant container comprising a housing (1) with a lid (11), characterized in that 
PATENTNI ZAHTJEVI Kontejner otporan na eksplozije koji se sastoji od kućišta (1) s poklopcem (11), pri čemu
preparation of perfluoro-2-methyl-2-penten-)3-enolate (intermediate (4)) in a Step 3 wherein Cat+ refers to a positively charged organic ion, alkaline metal cation or alkaline earth metal cation by reacting perfluoro-2-methyl-2-pentene with water and a base; and 
pripravu perfluoro-2-metil-2-penten-)3-enolata (intermedijer (4)) u Koraku 3 pri čemu se Cat+ odnosi na pozitivno nabijeni organski ion, alkalni metalni kation ili kation zemnoalkalijskog metala reakcijom perfluoro-2-metil-2-pentena s vodom i bazom; i
R2b and R2c are independently selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, fluorinated C1-C3 alkyl, cyano, C1-C3 alkoxy, and N(CH3)2; 
R3 je neovisno odabrana iz skupine koju čine halogen, C;-Cz alkil, fluorirani C,-C3 alkil, cijano, Cy-C3 alkoksi 1 NR+4Rx, gdje R4 i Ry su neovisno odabrane iz skupine koju čine
a main species HER2 antibody that binds to domain II of HER2, and comprises a variable light amino acid sequence provided as SEQ ID NO:3 and a variable heavy amino acid sequence provided as SEQ ID NO:4; and 
glavni rod HER2-protutijela, koji se veže na domenu II od HER2, i sadrži varijabilnu slabu aminokiselinsku sekvencu dobivenu kao SEQ ID NO:3 i varijabilnu jaku aminokiselinsku sekvencu dobivenu kao SEQ ID NO:4; i
reacting the compound of formula IV with chlorine gas at a temperature from 180°C to 250°C to the compound of formula I. 
reakcija spoja formule III s plinovitim klorom na temperaturi od 180°C do 250°C u spoj formule I.
A receptacle for containing and dispensing solid medicinal pills according to claim 1, wherein displacement of said closure from said closed position, to enable the dispensing of at least one pill from said chamber, is actuated by suction applied to said outlet and said closure by the mouth of the user. 
Spremnica (100; 200; 400; 500), namijenjena držanju i izdavanju čvrstih medicinskih pilula u skladu s patentnim zahtjevom 1, naznačena time što se pomicanje navedenog zatvarača (112; 212; 412; 512) iz navedenog zatvorenog položaja, kako bi se omogućilo izdavanje najmanje jedne pilule iz navedene komore (104; 204; 404), pokreće razlikom u tlaku zraka.
It is formed of a storage space designated to contain cigarettes within and a hinged lid joined with the storage space by means of an articulated joint placed on the rear wall, whereas the front wall of the lid is longer than the rear wall and the side walls are oblique. 
Sastavljena je od spremišnog prostora koji je namijenjen za držanje cigareta i preklopnog poklopca spojenog sa spremišnim prostorom pomoću zglobnog spoja smještenog na stražnjem zidu, dok je prednji zid poklopca duži od stražnjeg zida i bočni zidovi su kosi.
The pharmaceutical tablet especially in accordance with the preceding claims of any of claims 36 to 39 having a density of less than 1.20 g/cm3, preferably less than 1.19 g/cm3. 
Oblik za doziranje s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 28, naznačen time da je gustoća formulacije matrice s produljenim otpuštanjem a jednaka ili niža od 1.20 g/cm3, poželjno jednaka ili niža od 1.19 g/cm3.
ii) deprotecting the Ts group of the compound 8a under suitable conditions to form compound 9a: 
Ba ii) deprotekcije Ts grupe spoja &8a pod stabilnim uvjetima da bi se formirao spoj 9
The odor-absorbing composition according to claim 3, wherein said composition comprises an amount of said a-, B-, and Y-cyclodextrins in a weight ratio of about: 1:1.5:0.5. 
Sastav koji apsorbira neugodne mirise prema bilo kojem od prethodnih patentnih zahtjeva 11 i 12, naznačen time, da navedeni sastav obuhvaća količinu navedenih a-, B- i Y-ciklodekstrina u masenom omjeru od 1:1,5:0,5.
A compound of formula wherein W2 represents halo, and R1, R2, R3, R6, R7, q, p and r are as defined in claim 1. 
Spoj sa formulom [image] naznačen time da W2 predstavlja halo, i R1, R2, R3, R6, R7, q, p i r su kako je definirano u zahtjevu 1.
Example 1 - Large-scale industrial synthesis of the compound of formula 4-Br 
x Hr 4-Br koji se konačno prevede u amidin formule 1.
The polypeptide for us e according to claim 3, wherein the rate of inhibition is at least about 10-fold, 20-fold, 30-fold, or 40-fold faster than the rate of inhibition of mini-plasmin. 
Polipeptid prema zahtjevu 9, naznačen time da je stupanj inhibicije najmanje oko 10 puta, 20 puta, 30 puta ili 40 puta brži nego stupanj inhibicije mini-plazmina.
The invention also provides for a host transformed or transfected with a vector of the invention. 
Stanica domaćin, naznačena time što je se transformira ili transfektira vektorom u skladu s patentnim zahtjevom
A method of preparing a lyophilized or frozen preparation of a composition comprising particles comprising a drug, wherein the particles are coated with PEG, the method comprising adding PVA to an aqueous composition comprising the particles and lyophilizing or freezing the aqueous composition; 
Postupak pripreme liofiliziranog ili smrznutog pripravka sastava koji sadrži krute čestice koje sadrže lijek, pri čemu su čestice premazane polietilen glikolom, postupak sadrži dodavanje polivinil alkohola i sukroze u vodeni sastav koji sadrži čestice i liofiliziranje ili smrzavanje vodenog sastava, pri čemu polivinil alkohol je 13K do 31K;
A method of detecting BoNT/A activity, the method comprising the steps of: a) treating a cell from an established cell line with a sample comprising a BoNT/A, wherein the cell from an established cell line is susceptible to BoNT/A intoxication by a BoNT/A; b) isolating from the treated cell a SNAP-25 component comprising a SNAP-25 cleavage product having a carboxyl-terminus at the P1 residue of the BoNT/A cleavage site scissile bond; c) contacting the SNAP-25 component with an a-SNAP-25 antibody, wherein the a-SNAP-25 antibody binds an eptiope comprising a carboxyl-terminus at the P1 residue of the BoNT/A cleavage site scissile bond from a SNAP-25 cleavage product; and d) detecting the presence of an antibody-antigen complex comprising the a-SNAP-25 antibody and the SNAP-25 cleavage product; wherein detection by the antibody-antigen complex is indicative of BoNT/A activity. 
HR P20191886 T1 PATENTNI ZAHTJEVI ka Postupak otkrivanja aktivnosti BoNT/A kod sisavca koji sadrži korake: a. = tretiranje stanice iz uspostavljene stanične linije koja eksprimira SNAP-25 testnim uzorkom koji sadrži BoNT/A, pri čemu je stanica iz uspostavljene stanične linije osjetljiva na intoksikaciju BoNT/A, pri čemu je stanica iz uspostavljene stanične linije osjetljiva na intoksikaciju BoNT/A od oko 500 pM ili manje BoNT/A i pri čemu je navedena stanica izabrana iz skupine koja se sastoji od SiMa stanične linije i Neuro-2a stanične linije; b.
A compound according to claim 2 having the structure 
Spoj u skladu s patentnim zahtjevom 2, sa strukturom
or P1 hydroxyl protecting group such as a silyl protecting group, for 
hidroksilna zaštitna skupina kao što je silil zaštitna skupina, na primjer, TBDMS ili TES
The nonwoven wipe according to claim 1, wherein the opposite faces of the nonwoven wipe are opposite exterior faces of the nonwoven wipe, and the nonwoven wipe is a single ply nonwoven wipe. 
Netkani materijal prema zahtjevu 1, naznačen time da nasuprotna lica netkanog materijala predstavljaju nasuprotna vanjska lica netkanog materijala, a netkani materijal je jednoslojni netkani materijal.
A compound of claim 1 wherein the compound is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se spoj bira iz skupine koju čine:
The combined organic phases were washed with saturated aqueous sodium chloride (450 mL), dried over magnesium sulfate and the solvents evaporated off. 
Kombinirane organske faze isprane su zasićenom vodenom otopinom natrijevog klorida (450 mL), osušene na magnezijevom sulfatu, a otapala uparena.
The method according to claim 21, wherein said flat surface is made of a material which is capable of resuming its original shape after deformation and is temperature-resistant, comprising nitrile rubber, silicone, polychloroprene (neoprene) or microporous expanded EVA. 
Postupak u skladu s patentnim zahtjevom 22, naznačen time, da navedena ravna površina (20) izrađena je od materijala koji može ponovo zauzeti svoj početni oblik nakon deformacije (elastičan je) i otporan je na temperaturu, primjerice nitrilna guma, silikon, polikloropren ili mikroporozni ekspandirani EVA.
The dispensing closure according to claim 1 wherein the plastic cutter of the piston (4) comprises an extension of a circular edge of the piston (4). 
Zatvarač sustava razdjeljivanja prema zahtjevu 1, naznačen time, da je plastični rezač klipa (4) oblikovan kao produljenje kružnog brida klipa (4).
A compound of formula 8 wherein P is a protecting group such as acetyl. 
Spoj formule 8: Pri čemu je P zaštitna grupa kao što je acetil.
The method of Claim 1 further comprising resolving the compound of formula (I), or a pharmaceutically acceptable salt thereof, as a mixture of enantiomers, under suitable conditions to yield a compound of formula (I- S): or a pharmaceutically acceptable salt thereof, and a compound of formula (I-R): or a pharmaceutically acceptable salt thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se dodatno sastoji u razdvajanju spoja formule (1), ili njegove farmaceutski prihvatljive soli, u obliku smjese enantiomera, u uvjetima pogodnim za dobivanje spoja formule (I-$): ili njegove farmaceutski prihvatljive sol, i spoja formule (I-R): O
A population of mammalian stromal stem cells is thus provided, wherein 75% or more of the cells are positive for a cell surface marker, and wherein a corresponding cell surface marker is also expressed on a cell of at least one other mammalian species selected from human, mouse, rat, horse, rabbit and pig cells. 
HR P20150594 T1 PATENTNI ZAHTJEVI o o Populacija stromalnih matičnih stanica sisavca, naznačena time da je 30% ili više stanica pozitivno na Syndecan- Populacija stanica prema zahtjevu 1, naznačeno time da su stanice mišje, štakorske, konjske ili humane stanice.
A compound selected from the group consisting of: 
je odabran od vodika, alkila, cikloalkila, arila, heteroarila, i heterociklila.
In this manner it is possible to save on the thickness of the material, which forms the core, at the same time ensuring an adequate stiffness and resistance to deformation of the core. 
Na taj je način moguće uštedjeti na debljini materijala koji čini jezgru, te istodobno osigurati njezinu odgovarajuću čvrstoću i izdržljivost jezgre na deformaciju.
kurstaki, nucleopolyhedrovirus and an encapsulated delta-endotoxin of Bacillus thuringiensis. 
kurstaki, nukleopoliedrovirus i inkapsulirani delta-endotoksin Bacillus thuringiensis.
Number of averaged measurements 
Broj međunarodne objave:
Overall, there was no statistically significant drug effect on self-perception of sleep (LEEDS), alertness, contentedness and calmness (Bond-Lader VAS) and choice reaction time (CRT). 
U cjelini, nije bilo statistički značajnih učinaka lijekova na individualnu percepciju sna (LEEDS), pozornost, zadovoljstvo i mirnoću (Bond-Lader VAS) i odabrano reakcijsko vrijeme (CRT, prema engleskom:,,choice reaction time").
The compound according to any one of claims 1-3, wherein ring A is 3-chlorophenyl or 3-chloro-6-methylphenyl. 
Spoj sukladno zahtjevu 1 ili 3, pri čemu su dvije R'" spojene kako bi formirale prsten A čija je formula odabrana između: Q
The combined fireworks with launching pit and multi-channel fireproof structures of claim 3, characterized in that the fireproof bosses are circular bosses, and a recessed countersink is arranged in the exact center of the circular bosses within which provided with priming holes for mounting leads. 
Kombinirani vatromet s lansirnim oknima i višekanalnim vatrootpornim strukturama u skladu s patentnim zahtjevom 3, naznačen time što su vatrootporne izbočine kružne izbočine (10), a izdubljena udubina (11) je smještena u točnom središtu kružnih izbočina u kojima imaju upaljačke rupe (8, 9) za ugradnju vodova.
The antibody or antigen-binding fragment of any one of claims 1 to 9 for use in a method of increasing bone mineral content and/or bone mineral density in a warm-blooded animal or human. 
Antitijelo ili njegov fragment koji se veže na antigen prema bilo kojem od zahtjeva 1 do 7, naznačen time da je namijenjen uporabi u postupku povećanja mineralnog sadržaja kostiju i/ili mineralne gustoće kosti u toplokrvne životinje ili čovjeka.
An isolated antibody that specifically binds to B7-H1 having an amino acid sequence comprising: 
Izolirano protutijelo ili njegov vezni fragment, koje/koji se specifično veže na ljudski
an air conditioning unit (7) arranged for controlling a temperature and/or humidity in the cargo space (25); a generator for powering the air conditioning unit (7); and 
- jedinica (7) za klimatiziranje zraka, poželjno rashladna i/ili grijaća jedinica (7), postavljena za kontrolu temperature i/ili vlagu u teretnom prostoru (25);
The apparatus (10) of claim 8, characterized in that said coating system (600) has a spraying device that sprays said coating (2300) onto each of the carrier tablets (1000). 
Uređaj (10) u skladu s patentnim zahtjevom 8, naznačen time što navedeni sustav za oblaganje (600) ima napravu za prskanje koja naprska navedena obloga (2300) na svaku od nosivih tableta (1000).
A biocompatible, biodegradable, non-hydrolyzed PLG low-burst copolymer material for a controlled release formulation having a weight average molecular weight of about 10 kilodaltons to about 50 kilodaltons and a polydispersity index of about 1.4-2.0 and from which a removed copolymer fraction characterized by a weight average molecular weight of about 4 kDa to about 10 kDa and a polydispersity index of about 1.4 to 2.5 has been separated, and comprising copolymer molecular chains, wherein a predominant proportion of the molecular chains comprise predominantly lactate or lactide residues in at least one end domain of each molecular chain and predominantly glycolate or glycolide resides in an internal domain of each molecular chain. 
Postupak pripreme biokompatibilnog, biorazgradivog, ne-hidroliziranog PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja za oblik s kontroliranim oslobađanjem s prosječnom molekulskom masom od 10 kilodaltona do 50 kilodaltona i indeksom polidisperznosti od 1.4-2.0 i iz kojeg se izdvaja uklonjena frakcija kopolimera naznačena prosječnom molekulskom masom od 4 kDa do 10 kDa i indeksom polidisperznosti od 1.4 do 2.5, postupak obuhvaća izdvajanje uklonjene frakcije kopolimera naznačenog prosječnom molekulskom masom od 4 kDa do 10 kDa i indeksom polidisperznosti od 1.4 do 2.5 iz početnog PLG kopolimernog materijala, otapanje početnog PLG kopolimernog materijala u otapalu radi dobivanja otopine, zatim taloženje PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja dovođenjem u doticaj otopine s ne-otapalom i dobivanjem taloženog PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja, postupak ne obuhvaća korak hidrolize PLG kopolimera veće molekulske mase.
treating engine exhaust to recover exhaust heat and/or water from the engine, and 
- < obrađivanje ispušnih plinova motora radi obnavljanja ispušnih plinova i/ili vode iz motora, i
The method of paragraph 31, wherein the condition is gout, a recurrent gout attack, gouty arthritis, hyperuricaemia, hypertension, a cardiovascular disease, coronary heart disease, Lesch-Nyhan syndrome, Kelley-Seegmiller syndrome, kidney disease, kidney stones, kidney failure, joint inflammation, arthritis, urolithiasis, plumbism, hyperparathyroidism, psoriasis, sarcoidosis, hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency or a combination thereof. The method of paragraph 31, wherein the condition is gout. 
Spoj formule (I) kao što je utvrđeno u patentnim zahtjevima 1-9 za uporabu sukladno patentnom zahtjevu 10, pri čemu, stanje je giht, rekurentni napad gihta, gihtni artritis, hiperurikemija, hipertenzija, kardiovaskularnu bolest, koronarna bolest srca, Lesch-Nyhan-ov sindrom, Kelley-Seegmiller-ov sindrom, bolest bubrega, kamenac u bubregu, insuficijencija bubrega, inflamacija zgloba, artritis, urolitijaza, plumbizam, hiperparatiroidizam, psorijaza, sarkoidoza, deficijencija hipoksantin-guanin fosforiboziltransferaze (HPRT) ili njihova kombinacija.
recovering TF-bearing microvesicles from the cells of step (i) and 
obnavljanje mikrovezikula koje nose tkivni faktor iz stanica iz koraka (i) i
A device as claimed in claim 1 and wherein the container has catch means (22, 108, 112, 113, 310, 311, 312, 313) for holding the container closed until impact with water. 
Naprava u skladu s patentnim zahtjevom 1, naznačena time što spremnik ima sredstvo za hvatanje (22, 108, 112, 113, 310, 311, 312, 313), koje spremnik drži zatvorenim do udarca o vodu.
In a further embodiment, the present invention also relates to use of a compound of formula I for the preparation of a medicament for the treatment of panic attacks. 
U daljnjoj verziji, ovaj izum se odnosi 1 na uporabu spoja formule I za pripravu lijeka za liječenje napadaja panike.
the variant is a polypeptide that comprises two or more conservative amino acid substitutions compared to the replaced peptide, or 
(a) varijanta je polipeptid koji se sastoji od dvije ili više konzervativne supstitucije aminokiselina u usporedbi sa zamijenjenim peptidom, ili
An electrically heated smoking system according to any of claims 1 to 7, wherein the electrically insulating substrate is tubular and the one or more electrically conductive tracks are on the outside of the tubular electrically insulating substrate. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što se nanošenje navedene bezvodne tekućine na bazi silana provodi četkanjem ili valjanjem navedene bezvodne tekućine na bazi silana na profiliranu površinu.
is hydrogen, fluorine or hydroxyl; 
R; je vodik, fluor ili hidroksil;
L is selected from the group consisting of PR'3 and NR"3, 
Spoj izabran iz grupe koju čine: [image]
The process of paragraph 46 further comprising the step of treating said second mixture with a second base, resulting in a dynamic resolution of said second mixture, in which said B-isomer of Compound 17C is converted to a-isomer of Compound 17C, and a-isomer of Compound 17C is precipitated to produce Compound 17. 
Postupak u skladu s patentnim zahtjevom 36, naznačen time što se dodatno sastoji u koraku obrade navedene druge smjese drugom bazom, što uzrokuje dinamičko razdvajanje navedene druge smjese, u kojoj navedeni f3- izomer Spoja 17C se prevodi u a-izomer Spoja 17C, te se a-izomer Spoja 17C istaloži kako bi se dobilo Spoj 17.
It is preferred that the group A and the pyrazole group are not attached to adjacent ring members of the group E. For example, the pyrazole group can be attached to the group E in a meta or para relative orientation. 
Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time što su skupina A i pirazol spojeni na skupinu E u meta ili para položaju; tj. A i pirazol nisu spojeni na susjedne članove prstena skupine.
an antibody of any one of claims 1 to 7, or a pharmaceutical composition thereof; 
(a) protutijelo prema bilo kojem od zahtjeva 1 do 7, ili njegov farmaceutski sastav;